Questions: Mood Stabilizers: Lithium and Anticonvulsants

Question 1

A patient with bipolar disorder shows a predominantly depressive course — rare and mild manic episodes but frequent, severe depressive episodes. Based on the clinical profiles described, which mood stabilizer is most appropriate?

• A. Lithium, because it is the gold standard with the broadest evidence base
• B. Valproate, because it is preferred for mixed episodes and rapid cycling
• C. Lamotrigine, because its profile specifically favors prevention of depressive episodes
• D. No mood stabilizer — antidepressants alone are first-line for bipolar depression

Answer: (C)

Lamotrigine's clinical profile is described as 'almost the inverse of valproate — more effective at preventing depressive episodes than manic ones,' making it the agent of choice for depression-predominant or bipolar II courses. Lithium, while the gold standard overall, has stronger evidence for mania and suicide prevention. Using antidepressants as monotherapy in bipolar disorder risks triggering mania — this is explicitly listed as a Common Misconception.

Question 2

What is the core therapeutic challenge of treating bipolar disorder that makes it categorically different from treating unipolar depression?

• A. Bipolar patients metabolize medications faster due to mood-state-dependent liver enzyme activity
• B. The medication must prevent both mood poles without pushing too far in either direction — lifting mood risks mania, blunting mania risks depression — so agents must target the cycling mechanism rather than a specific pole
• C. There are no FDA-approved medications for bipolar disorder, so clinicians must rely on off-label agents
• D. Bipolar disorder requires combined antidepressant plus antipsychotic therapy in all cases

Answer: (B)

The Explainer states this directly: 'the same drug must prevent both mood poles simultaneously, or at least reduce their frequency and severity over time.' A medication that lifts mood too aggressively can precipitate mania; one that blunts mania too hard may deepen depression. Mood stabilizers solve this by targeting the cycling mechanism itself rather than aiming at a specific mood state — which is what distinguishes them from antidepressants or antipsychotics used in isolation.

Question 3

Lithium's anti-suicide effect in bipolar disorder appears to be independent of its antimanic properties, suggesting a separate mechanism such as reducing impulsivity and aggression.

• T. True
• F. False

Answer: True

The Explainer describes this as 'lithium's remarkable clinical distinction': the anti-suicide effect 'is robust across multiple studies and appears independent of its antimanic action — possibly because it reduces impulsivity and aggression.' This means lithium reduces suicidality through a mechanism beyond mood pole stabilization, which has implications for its use even in patients where other agents might control episodes equally well.

Question 4

Mood stabilizers such as lithium are effective for unipolar depression and can be used as monotherapy when standard antidepressants are insufficient.

• T. True
• F. False

Answer: False

This is explicitly listed as a Common Misconception: 'Mood stabilizers are not antidepressants and should not be used as monotherapy for unipolar depression — they specifically target mood cycling.' Lithium augmentation is sometimes used as an adjunct in treatment-resistant unipolar depression, but that is a specialist second-line strategy, not monotherapy. Mood stabilizers address the cycling mechanism of bipolar disorder, not the pathophysiology of unipolar depression.

Question 5

Why does lithium's narrow therapeutic window require ongoing monitoring, and which physiological systems must be tracked with long-term use?

Model answer: Lithium's therapeutic range is 0.6–1.2 mEq/L serum; even modestly exceeding this produces toxicity (tremor, confusion, ataxia; at higher levels, cardiac arrhythmia and seizures). Because lithium is renally cleared, any change in kidney function, hydration, or concurrent medications (NSAIDs, diuretics) can shift serum levels dangerously. Long-term monitoring must track: serum lithium levels (regularly), renal function (chronic lithium can impair kidney function), and thyroid function (lithium impairs thyroid hormone synthesis, potentially causing hypothyroidism).

The narrow therapeutic window means what is therapeutic under normal conditions can become toxic when a patient is dehydrated, switches to a low-salt diet, or starts an NSAID. Unlike most psychiatric medications where doses can be adjusted with minimal risk, lithium requires a clinician-patient partnership with explicit surveillance protocols. This is also why lamotrigine or valproate may be preferred in patients whose lifestyle makes stable serum levels difficult to maintain.